Money followed proof this week, more than it led it. A German startup got the EU Chips Act to fund manufacturing gear it had already tested with nine of the world's ten largest chipmakers.
A UK-spun cancer biotech got bought out only once its science held up in the clinic.
Even the week's biggest infrastructure bet, a Canadian launch pad for a rocket that has never reached orbit, was written to make the company prove itself before the real payments start.
Lead
Munich's QuantumDiamonds Becomes the Chips Act's First Manufacturing Bet on a Startup
QuantumDiamonds raised €91 million this week, split between a €15 million equity round led by World Fund and €76 million in non-dilutive funding from Germany's federal economy ministry and the state of Bavaria, approved under the EU Chips Act. It is the first startup ever approved for Chips Act manufacturing money.
Every other recipient so far has been an established player like GlobalFoundries or STMicroelectronics.
The company's technology uses nitrogen-vacancy diamond sensors to find hidden defects in chips through non-destructive current imaging, compressing an inspection process that normally takes weeks into about two minutes without stopping the production line. Nine of the world's ten largest chipmakers have already tested it.
The funding builds a €152 million production facility in eastern Munich, opening in the second half of 2026, and QuantumDiamonds plans to more than double its 70-person engineering team over the next year.
That order of operations matters. Recent Chips Act stories in this briefing have run the other way: state capital committed to design houses and fabs years before they ship a product.
Here, customer validation came first and the public money followed it.
(TechCrunch) (The Quantum Insider)
Biotech & Life Sciences
Novartis Pays Up to $1.5 Billion for a Cancer Biotech Spun Out of Imperial College and the Crick
Myricx Bio, founded in 2019 by researchers from Imperial College London and the Francis Crick Institute with backing from Sofinnova Partners and Brandon Capital, agreed on July 6 to be acquired by Novartis for up to $1.5 billion, with $1.1 billion paid upfront in cash. The company's two lead antibody-drug conjugates target B7-H3 and HER2 across a range of solid tumours.
The deal is Sofinnova's seventh exit in three years and is expected to close in the second half of 2026, subject to regulatory approval. An academic spinout reaching a billion-dollar pharma buyout inside seven years is a fast track by biotech standards, and it says something about how much acquirer appetite there still is for differentiated ADC science out of Europe.
(BioSpace)
Materials & Manufacturing
Uplift360 Signs a Multi-Year Deal to Supply Luxembourg's Military With Recycled Composite Materials
Uplift360, a Bristol-founded startup that chemically regenerates carbon fibre and aramid recovered from retired aircraft including Eurofighter Typhoon components, signed a multi-year framework agreement on July 9 with Luxembourg's Directorate of Defence. The deal builds on an eight-year partnership and ties into the multinational Defence Critical Raw Materials project launched at the NATO Summit Defence Industry Forum.
Under the agreement, Uplift360 becomes a strategic materials partner producing high-performance composites exclusively from European sources, cutting the Luxembourg military's exposure to imported supply chains. A small country's defence directorate backing a homegrown circular-materials supplier shows NATO's materials-sovereignty push moving past framework papers into production contracts.
Finnish Startup CurifyLabs Raises €12 Million to Take 3D-Printed Medicine Into the US
Helsinki-based CurifyLabs closed a €12 million Series A on July 6, co-led by Sandwater and HealthCap with Tesi and Lifeline Ventures also participating. Its Compounding System Solution pairs software and GMP-manufactured excipient bases with 3D printing to automate the preparation of personalised medication doses.
The round funds a push into the US market alongside supply-chain and product work at home. Most of the traffic in health-tech manufacturing runs the other way, with American tools entering Europe, so a Finnish additive-manufacturing platform expanding outward is worth flagging.
(Tech.eu)
Robotics & Automation
An Ex-Tesla Optimus Engineer Launches a Paris Humanoid Startup Built for Europe First
Rémi Cadène, who spent three years on Tesla's Optimus and Autopilot teams before leading Hugging Face's open-source LeRobot library, unveiled his own startup, UMA, and its humanoid robot Northstar on July 7. The prototype was designed and assembled in Paris over nine months by a small team.
UMA is backed by Greycroft, Relentless, and Unity Growth, with angel investors including Yann LeCun, Datadog CEO Olivier Pomel, and Hugging Face co-founder Thomas Wolf. The company says 50 potential customers are evaluating the robot for manufacturing and logistics work, with industrial pilots targeted for later this year.
Unlike most humanoid makers chasing the US or China, UMA is explicitly building around Europe's aging workforce and dense industrial base.
(Electrek)
One to Watch
Isar Aerospace Bets on a Canadian Launch Pad Before Spectrum Has Reached Orbit Once
Isar Aerospace signed a binding $112.5 million facilities agreement on July 7 with Maritime Launch Services for a dedicated pad at Spaceport Nova Scotia, its first North American site, inked at NATO's defence industry summit in Ankara. The contract's payment schedule gives Isar room to prove itself first: quarterly fees don't start until after a 30-month waiver period.
Spectrum's second flight, "Onward and Upward," has been scrubbed five times since January and is now targeted no earlier than July 31. Every projection behind the Nova Scotia deal, and Germany's European Launcher Challenge funding tied to it, assumes that flight succeeds.
Watch whether it does.